ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ENTA Enanta Pharmaceuticals Inc

13.46
0.95 (7.59%)
Feb 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 199,663
Bid Price 13.14
Ask Price 13.84
News -
Company Name Stock Ticker Symbol Market Type
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.95 7.59% 13.46 20:00:00
Open Price Low Price High Price Close Price Prev Close
12.58 12.505 13.50 13.46 12.51
Trades Volume VWAP Dollar Volume Avg Volume
2,549 199,663 $ 12.97 $ 2,589,428 -
Last Trade Time Type Quantity Stock Price Currency
19:29:33 20 $ 13.17 USD

Enanta Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
285.18M 21.16M - 79.2M -133.82M -6.33 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Enanta Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ENTA Message Board. Create One! See More Posts on ENTA Message Board See More Message Board Posts

Historical ENTA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Enanta Pharmaceuticals Description

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Your Recent History

Delayed Upgrade Clock